Clinical Trials

Breast Neoplasms

NCT07060807 2026-03-16

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

Phase 3 Recruiting

1,000 enrolled

Breast Neoplasms

NCT06312176 2026-03-13

MK-2870-010

Phase 3 Recruiting

1,200 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms

NCT04895358 2026-03-11

KEYNOTE-B49

340 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms, Neoplasm Metastasis

NCT06926868 2026-03-11

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

Phase 2/3 Recruiting

500 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06018337 2026-03-05

A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)

541 enrolled

Breast Neoplasms

NCT04494425 2026-03-04

DB-06

866 enrolled 25 charts 1 FDA

Breast Neoplasms

NCT05374512 2026-01-27

A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)

644 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT07071337 2025-12-11

A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy

Phase 3 Recruiting

430 enrolled

Breast Neoplasms

NCT03734029 2025-10-06

Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

557 enrolled 22 charts 1 FDA

Breast Neoplasms, Neoplasm Metastasis

NCT05840211 2025-10-03

ASCENT-07

654 enrolled

BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms

NCT06769425 2025-06-24

HS-10502

Phase 1 Recruiting

157 enrolled

Breast Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms

NCT04247126 2023-10-27

A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors

BreastGastrointestinalThoracic

105 enrolled

Breast Neoplasms, Pancreatic Neoplasms, Small Cell Lung Carcinoma

NCT03961698 2023-08-14

MARIO-3

Phase 2 Unknown

91 enrolled

BreastGenitourinary

Breast Neoplasms, Carcinoma, Renal Cell, Triple Negative Breast Neoplasms

NCT04335006 2023-05-06

A Phase 3 Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib, Carelizumab Plus Nab-paclitaxel, and Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer.

Phase 3 Terminated

80 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02915744 2023-04-14

ATTAIN

Phase 3 Completed

178 enrolled 37 charts

Breast Neoplasms, Carcinoma, Neoplasm Metastasis

NCT02322814 2023-04-13

A Study of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as Initial Treatment for Participants With Triple-Negative Breast Cancer That Has Spread

169 enrolled 31 charts

Breast Neoplasms

NCT02229149 2022-12-02

Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer

33 enrolled

Breast Neoplasms

NCT04132817 2022-12-02

A Study of Multiple Immune and Disease Treatment Combinations in Participants With ER+HER2- Breast Cancer That Has Spread

12 enrolled

Breast Neoplasms

NCT01572038 2020-09-25

PERUSE

Phase 3 Completed

1,436 enrolled 53 charts

Breast Neoplasms

NCT01803282 2020-06-02

Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors

BreastGastrointestinalThoracic

236 enrolled 21 charts

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Colorectal Neoplasms

NCT00394082 2019-11-25

ABI-007 In Combination With Bevacizumab in Women With Metastatic Breast Cancer

Phase 2 Completed

50 enrolled 17 charts

Breast Neoplasms

NCT00456846 2019-11-22

First Line Therapy for Patients With Metastatic Breast Cancer

123 enrolled 19 charts

Breast Neoplasms

NCT02309177 2019-05-31

Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer

BreastGastrointestinalThoracic

114 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Pancreatic Neoplasms, Triple Negative Breast Neoplasms

NCT01881230 2019-02-21

tnAcity

Phase 2/3 Completed

191 enrolled 22 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02019277 2018-09-13

SAPPHIRE

Phase 3 Completed

50 enrolled 18 charts

BreastGastrointestinalLymphoid

Breast Neoplasms

NCT01929941 2018-01-17

An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies

Phase 1 Terminated

5 enrolled

Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Pancreatic Neoplasms

NCT02555696 2017-02-23

Abraxane in Treatment of Metastatic Breast Cancer

Completed

203 enrolled

Breast Neoplasms

NCT02064829 2016-03-25

TRIBECA

Phase NA Completed

111 enrolled

Breast Neoplasms

NCT00479856 2012-06-05

Lapatinib In Combination With Chemotherapy In Subjects With Relapsed Breast Cancer

9 enrolled 7 charts